A Bucks County woman is speaking out after her insurance company decided to no longer cover weight loss drugs.
A non-opioid painkiller from Vertex Pharmaceuticals could become a blockbuster, but questions remain on whether it will prove ...
Eli Lilly (LLY) revised its revenue outlook on Tuesday for the fourth quarter of 2024 on weaker-than-expected demand for its ...
Zepbound is a dual-activating medication that combines glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like ...
The U.S. Food and Drug Administration (FDA) recently approved ... Zepbound offers a new approach to managing OSA symptoms while also promoting significant weight loss. Zepbound is an injectable ...
21 (UPI) --Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has ... knee arthritis pain to curbing asthma. Friday's FDA approval of Zepbound for treating moderate to severe sleep ...
The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...
The Food and Drug Administration today approved Eli Lilly’s weight-loss treatment ... Regulators can expand approval for medicines if new data shows them to be effective in other therapeutic ...
Eli Lilly stock rose Monday after Zepbound received Food and Drug Administration (FDA) approval as a treatment for obstructive sleep apnea among adults with obesity.
Photo courtesy Eli Lilly & Co. Dec. 21 (UPI) --Zepbound, the new GLP-1 weight-loss drug from Eli Lilly ... pain to curbing asthma. Friday's FDA approval of Zepbound for treating moderate to ...